Good
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment with FDA-labeled content is good. Most foundational claims about indication, starting dose, contraindications, warnings (including boxed warning for heart failure), drug interactions, monitoring, and administration are supported. Several statements are inaccurate or misleading (notably max dose statements and some dosing nuances), and a number of statements are not explicitly supported by the labeled sections provided. Some expected label details are missing or not clearly evidenced in the supplied excerpts.
Category Scores
Accurate Statements
Pioglitazone is a thiazolidinedione (TZD) that improves insulin sensitivity in people with type‑2 diabetes.
Indications and Usage (1)
Type‑2 diabetes patients who need additional glucose control beyond diet, exercise, and first‑line drugs (e.g., metformin).
Indications and Usage (1)
Not recommended for: Type‑1 diabetes (insulin‑dependent).
Indications and Usage (1)
Not recommended for: Diabetic ketoacidosis.
Indications and Usage (1)
Not recommended for: Severe heart failure (NYHA Class III–IV).
Warnings and Precautions (5.1), Boxed Warning
HbA1c should be checked every 3–6 months to assess efficacy.
Indications and Usage (1)
Weight and edema should be checked at each visit.
Indications and Usage (1)
Bone density should be checked if you’re on long‑term therapy, especially women over 50.
Fractures (5.6)
Concomitant use with insulin or sulfonylureas increases risk of hypoglycemia; reduce dose or monitor glucose more frequently.
Drug Interactions (7)
Digoxin levels may increase when pioglitazone is used with digoxin; check digoxin levels if clinically indicated.
Drug Interactions (7)
Antacids/Calcium decrease absorption; Take pioglitazone at a different time.
Drug Interactions (7)
Statins increase risk of myopathy; Monitor CK if high‑dose statin is used.
Drug Interactions (7)
Take with food to reduce gastrointestinal upset.
Patient Counseling Information (17)
Consistency matters: taking at the same time each day helps maintain steady blood levels.
Patient Counseling Information (17)
Do not skip doses—if you miss a dose, take it as soon as you remember, unless it’s close to the next dose.
Patient Counseling Information (17)
Report symptoms: sudden swelling, breathing trouble, unexplained weight gain, or dark urine right away.
Patient Counseling Information (17)
A 15 mg daily dose of pioglitazone is the usual starting point for most adults with type‑2 diabetes.
Recommendations for All Patients (2.1)
It’s effective, but like all medications, it carries a risk of side‑effects, especially fluid retention and bone issues.
Indications and Usage (1), Fractures (5.6)
If you’re on pioglitazone or considering it, keep regular appointments with your clinician, monitor your labs and weight, and let them know about any new symptoms.
Patient Counseling Information (17)
Unsupported Statements
It’s usually sold as 15 mg tablets, which are the standard dose for most patients.
Partially supported; label confirms 15 mg as a strength but does not state 'usually sold' as a market form.
Starting dose: 15 mg once daily, usually taken in the evening or at bedtime.
Partially supported; label states starting dose 15 mg once daily but time of day is not specified in cited sections.
Starting low helps limit side‑effects such as fluid retention, weight gain, and edema.
Not explicitly stated in cited sections as a dosing strategy.
It gives clinicians a simple “step‑up” path if more control is needed.
Not explicitly described with the exact phrasing in cited sections.
Weight gain occurs in 5–10%.
Incidence not specified in the cited label sections.
Bone fractures occur in 10% in older adults, especially in women ≥50 yr.
Incidence not stated in the cited label sections.
Hepatic injury occurs rarely (≈0.2%).
No specific incidence percentage stated in the cited sections.
Kidney function (serum creatinine, eGFR) before starting and periodically if renal function is borderline.
Renal monitoring guidelines are not presented in the cited label portions.
Liver enzymes (ALT/AST) before initiation and annually.
Annual liver enzyme monitoring is not explicitly supported in the cited material; baseline monitoring is discussed but annual monitoring is not clearly stated in the cited sections.
Bladder cancer risk shows a slight increase; long-term users >3 years should be monitored (no routine screening, but report symptoms).
Partially supported; label notes potential bladder cancer risk and symptoms monitoring, but routine screening is not recommended.
Contradictions
Low
AI Statement
If the target HbA1c isn’t reached after several weeks, the dose can be increased to a maximum of 30 mg daily (15 mg twice a day or 30 mg once a day).
Label Reference
Recommendations for All Patients (2.1)
Low
AI Statement
Never exceed 30 mg daily.
Label Reference
Recommendations for All Patients (2.1)
Low
AI Statement
Not recommended for: Advanced liver disease.
Label Reference
Hepatic Effects (5.3)
Low
AI Statement
Liver enzymes before initiation and annually.
Label Reference
Indications and Usage (1)
Important Omissions
Storage and handling
Importance:
Moderate
Pregnancy use details (8.1) and specific population guidance
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Overall claims largely align with label safety signals (edema, fractures, hepatic monitoring, bladder tumor considerations). Notable misstatements involve maximum dosing and some dosing rationale; no high-severity conflicts identified that would imply high patient risk beyond known label risks.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Max dose misstatement (claim 4/5) and some dosing rationale items are not fully supported by the labeled sections provided.
Suggested Improvement
Correct dosing bounds to reflect label maximum of 45 mg daily; avoid implying 'lowest dose' as universally optimal; ensure administration timing and meal-related guidance aligns with the label (label allows with or without meals; avoid asserting mandated timing). Consider clarifying which statements are supported vs. partial/unsupported to reduce misinterpretation.